Johnson & Johnson Delivered 'Immaculate' Prostate Cancer Data at ESMO. Here's Why Investors Should Care
Johnson & Johnson's $3.05 billion Halda bet is already paying off in the clinic.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.